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Abstract: Platelet count reflects the severity and prognosis of multiple diseases. Additionally,
alterations in gut microbiota have been linked to several chronic diseases. The purpose of this
study was to investigate the association between gut microbiota and platelet count. We selected 1268
subjects with fecal 16S RNA gene sequencing data from a Healthcare Screening Center cohort. Based
on the third quartile of platelets (277 × 109/L), we compared the gut microbiota between the upper
quartile (n = 321) and lower three quartiles groups (n = 947). The upper quartile group had lower alpha
diversity based on observed amplicon sequence variants (q = 0.004) and phylogenetic index (q < 0.001)
than the lower three quartiles group. Significant differences were also found in the weighted UniFrac
distance (q = 0.001) and Jaccard dissimilarity (q = 0.047) beta diversity measures between the two
groups. Compared with the lower three quartiles group, the upper quartile group exhibited decreased
relative abundances of the genus Faecalibacterium, which was also inversely correlated with the platelet
count. Increased platelet count was associated with reduced diversity in gut microbiota and lower
abundances of Faecalibacterium with beneficial gut bacteria spices F. prausnitzii, suggesting that an
increased platelet count, even within normal range, may adversely affect gut microbial diversity
and composition.
Keywords: gut microbiota; 16S RNA; platelet; thrombocytosis; Faecalibacterium
1. Introduction
Humans consistently interact with their microbiota, which is defined as the collection of
microorganisms living inside and on the human body. The bacteria of the microbiota and their
genomes are collectively referred to as the microbiome [1,2]. The human gut contains the greatest
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number and density of bacteria in the human body, and its microbiota is host-specific based on heritable
components [3] and is modified by acquired factors such as diet, drugs, surgery, and aging [4–7].
The gut microbiota plays important roles in the development and progression of numerous medical
conditions, including obesity [8], inflammatory bowel disease (IBD) [9], cardiovascular disease [10,11],
and neurodegenerative diseases [12]. The recent terms “gut-brain axis” and “gut-lung axis” indicate
that gut microbiota can influence multiple organs and systems by producing metabolites and chemicals,
and causing the release of inflammatory cytokines [13,14].
Thrombocytosis is mainly derived from secondary causes with the exception of essential
thrombocytosis, which is due to clonal thrombopoiesis. Not only acute conditions such as infection,
inflammation, and blood loss, but also chronic conditions (e.g., iron deficiency, chronic inflammatory
or infectious diseases, malignancy) contribute to reactive thrombocytosis [15]. In addition, platelets
regulate the immune system by releasing pro-inflammatory factors and activating innate immunity [16].
Although thrombocytosis has been demonstrated to predict the prognosis of several pathologic
conditions [17–20], the impact of relative increases in platelet count within the normal limit on the
human body remains unclear. Because the gut microbiota is a sensitive marker of several diseases,
reflecting an individual’s immune system and inflammatory status, we hypothesized that small
changes in platelet count might lead to changes in the gut microbiome.
We previously demonstrated that the neutrophil-to-lymphocyte ratio and inflammatory markers
were associated with the gut microbiome in a Korean population [21]. Here, we aimed to evaluate
the association between the gut microbiota and platelet count in a Korean population using health
screening data.
2. Materials and Method
2.1. Study Population
We screened 1463 Korean men and women between 25 and 78 years old who visited Kangbuk
Samsung Hospital Healthcare Screening Center in the Republic of Korea for a comprehensive annual
or biennial physical examination from June to September 2014 (Figure 1).
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Figure 1. Flowchart of subjects’ enrollment. NSAID, non-steroidal anti-inflammatory drugs; Lower 3Q,
<75th percentile for platelet count; Upper Q, ≥75th percentile for platelet count.
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Among 1463 subjects with fecal DNA samples for 16S rRNA sequencing, 195 subjects were
excluded for the following reasons: medications that could affect the gut microbiome and/or platelet
function (n = 182), lack of baseline platelet count (n = 5), or less than 1,000 sequences per sample (n = 8).
Additionally, five subjects were excluded because their platelets were not within the newly devised
reference range (between 100 and 500 × 109/L) based on the distribution of platelet counts excluding
outliers. Finally, 1268 subjects were included in our study.
2.2. Study Design
We assessed correlations between platelet count and the relative abundances of gut microbiota.
Our subjects were divided into two groups, the lower three quartiles (3Q; n = 947) and the upper
quartile (n = 321) based on third quartile platelet count (3Q = 277 × 109/L). The diversity and
composition of the gut microbiota were compared between the upper Q and lower 3Q groups. Because
the normal range of platelet count varies by sex [22,23], subgroup analysis was performed using the
third quartile platelet count according to sex (268 × 109/L for men and 294 × 109/L for women).
Demographic data, laboratory findings, and medical and diet histories were retrospectively
reviewed through medical records and questionnaires taken at the time of sample collection.
This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital (KBSMC
2013-01-245-12) and written informed consent was provided by all subjects.
2.3. DNA Extraction and 16S Gene rRNA Sequencing for Bacterial Communities
Fresh fecal samples were obtained immediately after defecation and stored at −70 ◦C within 24 h
until DNA extraction. Genomic DNA was extracted using the MO Bio PowerSoil® DNA Isolation
Kit (MO BIO Laboratories, Carlsbad, CA, USA) in accordance with the manufacturer’s instructions.
The methods used to amplify and sequence the DNA were detailed in our previous study [24]. Briefly,
the universal primers 341F and 805R were used to amplify genomic DNA in the variable V3 and V4
regions of the 16S rRNA genes. The 16S rRNA sequencing of all samples was performed with the read
length of 300 bp paired-end using the Illumina MiSeq platform (Illumina, San Diego, CA, USA) with
the manufacturer’s specifications [25].
2.4. Compositional Analysis of 16S rRNA Gene
The sequence quality control and feature table construction were performed using DADA2 [26] of
QIIME2 plugins (version 2018.08, https://qiime2.org) [27,28]. Low quality sequences and chimeric
sequences were excluded. The amplicon sequence variants (ASVs) were produced by denoising
with DADA2 and regarded as 100% operational taxonomic units (OTUs) [29]. After denoising,
the paired-sequences were merged and, after that, the chimeras were removed. We created the
feature table, including the abundance table and the representational sequence file. The taxonomic
classification was performed using a pre-trained Naïve Bayes classifier and the q2-feature-classifier
plugin. This classifier was trained on the V3–V4 region containing the gene from 99% OTUs files in the
Greengenes 13_8 release of 16S rRNA gene sequences [30].
2.5. Statistical Analysis
All continuous variables were presented as mean ± standard deviation (SD) and categorical
variables were expressed as number (%). QIIME2 (version 2018.08) was used to analyze the diversity
and composition of gut microbiota between groups [29]. Before diversity analyses, the feature
tables were rarefied with 1000 sample depth evenly by random subsampling. Alpha diversity
indices, which measures the number of distinct ASVs in each sample, was expressed using the
actual number of different taxa observed in a sample as the non-phylogenetic index (“Observed
ASVs”) and a phylogenetic diversity (PD) measurement, Faith’s PD, which incorporated phylogenetic
difference between ASVs [31]. Alpha diversity was also measured using the following two
non-phylogenetic methods: the Shannon index, which is measured by accounting for both evenness and
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richness [32], and the Pielou’s evenness, which quantifies how equal the community is numerically [33].
The difference in alpha diversity between groups was calculated using the Kruskal-Wallis test. The beta
diversity between groups was assessed using with following three methods: unweighted UniFrac
distance as phylogenetic and qualitative index; weighted UniFrac distance as phylogenetic and
quantitative index for abundance differences [34]; Jaccard dissimilarity as non-phylogenetic and
qualitive index for presence/absence differences [35]. Differences in beta diversity between platelet
groups was compared using pairwise permutational multivariate analysis of variance (PERMANOVA
with 999 permutations) [36]. For composition analysis, taxa with low abundance (less than 10%)
were filtered. Analysis of composition of microbiome (ANCOM) in QIIME2 was used to compare
the log-ratio different abundances of gut microbial taxa in the upper and lower 3Q groups [37].
The correlation between the abundance of taxa and platelet count and comparison of the abundance of
taxa between the upper and lower 3Q groups were assessed using multivariate association with linear
models (MaAsLin, version 1.0.1, http://huttenhower.sph.harvard.edu/maaslin) software package [38]
for R (version 3.5.1, URL http://www.R-project.org). Analyses included covariate adjustments for
age, sex, smoking status, and body mass index (BMI), all of which could affect gut microbiome
composition [39–42]. All analyses using MaAsLin were performed with the default settings and
presented as covariate-adjusted coefficients (CE). The differentially abundant taxa between the two
groups at different taxonomy levels were presented as W-statistics.
Additionally, microbial community function was evaluated by predictive metagenome (microbial
DNA) analysis using PICRUSt (Phylogenetic Investigation of Communities by Reconstruction
of Unobserved States) [43]. PICRUSt is a developed phylogeny-based computational tool that
predicts the functional capacity of microbial communities by correlating the species present to
reference databases of microbial genomes. We performed PICRUSt with de-novo variants according
to a recent manual (https://github.com/LangilleLab/microbiome_helper/wiki/PICRUSt-Tutorial-
with-de-novo-Variants). DADA2 variants were normalized using the 16S rRNA copy number,
and KEGG (Kyoto Encyclopedia of Genes and Genomes) orthologs (KOs) were predicted. Results that
aggregated to level three of the KEGG analysis module were further explored with STAMP (statistical
analysis of taxonomic and functional profiles) version 2.1.3 [44], using two-group analysis module.
The resulting p-values were corrected for multiple comparisons on the number of pathways using FDR
(Benjamini-Hochberg, q-value).
3. Results
3.1. Baseline Characteristics
Of the total 1268 subjects (mean age: 45.4 years, men: 62.1%), 947 and 321 subjects were classified
into the lower 3Q and upper Q groups, respectively (Table 1).
Table 1. Baseline demographics and laboratory findings between the upper and lower 3
quartiles groups.
Variables Lower 3Q Upper Q Total p-Value
No. 947 321 1268
Age, years 45.7 ± 9.0 44.7 ± 8.4 45.4 ± 8.8 0.093
Male sex 634 (66.9%) 153 (47.7%) 787 (62.1%) <0.001
Body mass index, kg/m2 23.6 ± 3.1 23.6 ± 3.1 23.6 ± 3.1 0.748
Smoking status 0.056
Never 505 (57.0%) 195 (64.8%) 700 (59.0%)
Former 216 (24.4%) 58 (19.3%) 274 (23.1%)
Current 165 (18.6%) 48 (15.9%) 213 (17.9%)
Smoking amount, pack-years 14.4 ± 10.8 15.4 ± 13.9 14.6 ± 11.6 0.483
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Table 1. Cont.
Variables Lower 3Q Upper Q Total p-Value
Laboratory finding
Platelet, 109/L 224.4 ± 33.5 314.9 ± 36.4 247.3 ± 52.2 <0.001
White blood cell, 103/mm3 5.6 ± 1.4 6.4 ± 1.6 5.8 ± 1.5 <0.001
Neutrophil, % 54.9 ± 8.0 56.0 ± 7.7 55.2 ± 8.0 0.037
Lymphocyte, % 33.5 ± 7.4 34.9 ± 7.1 35.4 ± 7.3 0.167
Eosinophil, % 2.6 ± 2.1 2.4 ± 1.9 2.6 ± 2.4 0.189
Basophil, % 0.4 ± 0.3 0.5 ± 0.3 0.5 ± 0.3 0.003
Monocyte, % 6.5 ± 1.6 6.2 ± 1.5 6.4 ± 1.6 0.003
Neutrophil/lymphocyte ratio 1.7 ± 0.7 1.7 ± 0.6 1.7 ± 0.7 0.238
Hematocrit, % 42.3 ± 3.6 40.9 ± 4.0 42.0 ± 3.7 <0.001
Iron, µg/dL 122.0 ± 41.4 115.5 ± 4.5.6 120.4 ± 42.6 0.045
Ferritin, ng/mL 161.1 ± 135.1 138.0 ± 128.3 155.3 ± 133.7 0.008
C-reactive protein, mg/dL 0.1 ± 0.2 0.1 ± 0.1 0.1 ± 0.2 0.808
Data are presented as mean (standard deviation) or number (%). Lower 3Q, <75th percentile for platelet count;
Upper Q, ≥75th percentile for platelet count.
The upper Q group had fewer men than the lower 3Q group. Additionally, the upper Q
group had more total white blood cells (WBCs), neutrophils, and basophils, but lower levels of
monocytes, hematocrit, serum iron, and ferritin compared to the lower 3Q group. There were no
significant differences in comorbidities or nutritional status between the two groups (Supplementary
Tables S1 and S2).
Because the sex distribution between the two groups was different, we performed sub-group
analyses according to sex using sex-specific third quartiles of platelet count (268 × 109/L for men and
294 × 109/L for women). In men, WBC and basophil counts were significantly different between the
lower 3Q (n = 589) and upper Q (n = 198) groups (Supplementary Table S3). In women, the upper Q
group (n = 121) had a higher BMI, higher levels of WBC and basophils, and lower levels of hematocrit,
serum iron, and ferritin compared with the lower 3Q group (n = 360).
3.2. Comparison of Alpha Diversity between the Upper Quartile and Lower Three Quartiles Groups
The upper Q group had significantly lower alpha diversity measurements including observed
ASVs (q = 0.004), PD (q < 0.001) and Shannon index (q = 0.002) compared to the lower 3Q group
(Figure 2). However, the evenness was not significantly different between the two groups (q = 0.254).
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Figure 2. Comparison of alpha diversity indexes between the upper and lower three quartiles groups.
(A) Observed amplicon sequence variants (ASVs), (B) phylogenetic diversity, (C) Pielou evenness, and
(D) Shannon’s index. Lower 3Q, <75th percentile for platelet count; Upper Q, ≥75th percentile for
platelet count. * q < 0.05.
Subgroup analyses of men showed that alpha diversity in the upper Q group as measured by
observed ASVs (q = 0.048), PD (q = 0.007), and the Shannon index (q = 0.009) was also lower than in
the lower 3Q groups (Supplementary Figure S1). Additionally, the evenness between the two groups
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approached significance (q = 0.078). In contrast, in women, no significant differences in alpha diversity
between the two groups were observed (Supplementary Figure S2).
3.3. Comparison of Beta Diversity between the Upper Quartile and Lower Three Quartiles Groups
Significant differences in beta diversity between the upper Q and lower 3Q groups were identified
as measured by unweighted UniFrac distance (q = 0.001) and Jaccard dissimilarity (q = 0.017), but not
by weighted UniFrac analysis (q = 0.156; Table 2 and Supplementary Figure S3).
Table 2. The statistical significances of beta diversity distances from lower three quartiles groups based
on different measurement methods.
Beta Diversity Indices Total Male Female
Unweighted UniFrac distance 3.472 * 2.964 * 1.598
Weighted UniFrac distance 1.696 3.074 * 1.643
Jaccard dissimilarity 1.299 * 1.167 1.059
The values are presented with the pseudo-F statistic from 999 permutation. * q < 0.05.
Subgroup analyses of men showed that beta diversity measured by unweighted (q = 0.003)
and weighted UniFrac distance (q = 0.020) was also significantly different between the two groups
(Supplementary Figure S4), and the difference in beta diversity based on Jaccard dissimilarity
approached statistical significance (q = 0.076). In contrast, the beta diversity measurements between
the upper Q and lower 3Q groups were similar in women, with only a trend toward significance for
the unweighted UniFrac distance (q = 0.052; Supplementary Figure S5).
3.4. Comparison of the Microbial Composition between the Upper Quartile and Lower Three Quartile Groups
Significant differences in relative abundances between the upper Q and lower 3Q groups were
assessed from phylum to species level using the ANCOM method (Table 3). The upper Q group had
significantly reduced abundance of Clostridia class, Clostridiales order, Ruminococcaceae family, and
Faecalibacterium genus compared to the lower 3Q group. The W is interpreted as follows: the “W = 10”
of Clostridia indicates that the class was detected to be significantly different relative to 10 other classes
between the two groups.
Table 3. The comparison of microbiome composition between the upper and lower three
quartiles groups.
Level Taxonomic Assignment W a Normalized W b
Class k__Bacteria; p__Firmicutes;c__Clostridia * 10 0.32
Order k__Bacteria; p__Firmicutes;c__Clostridia; o__Clostridiales * 21 0.44
Family
k__Bacteria; p__Firmicutes;
c__Clostridia; o__Clostridiales;
f__Ruminococcaceae *
34 0.40
Genus
k__Bacteria; p__Firmicutes;
c__Clostridia; o__Clostridiales;
f__Ruminococcaceae;
g__Faecalibacterium *
140 0.65
* Decreased in the upper group. k, kingdom; p, phylum; c, class; o, order; f, family; g, genus; a if W = X for taxon k,
then H0k is rejected X times. The W statistic for a significant difference in taxa relative to other taxa at each taxa
level is represented; b W statistics are normalized with each total taxa number (W statistic/total taxa number (class:
31, order: 48, family: 85, genus: 214)).
Among men, no significant differences in the relative abundances of taxa between the upper Q
and lower 3Q were identified. However, the upper Q group in women showed a remarkably decreased
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abundance of the Ruminococcaceae family and Faecalibacterium genus compared to the lower 3Q group
(Supplementary Table S4). In contrast, the Chloroplas class and Aeromonadales order was increased
in the female upper Q group, while the Mollicutes class was decreased in the female upper Q group
compared with the female lower 3Q group.
3.5. Correlation between Platelet Count and Gut Microbiota
Based on a MaAsLine analyses adjusted for age, sex, smoking status, BMI, total WBC count,
and hematocrit in all subjects, the relative abundance of several bacteria decreased as the platelet
count increased (Table 4). The platelet count negatively correlated with the genera Faecalibacterium
(CE: −0.00022, q = 0.0016).
Table 4. The correlation between identified taxa and platelet count on MaAsLin analysis.
Order Family Genus n Not toZero (%) CE p-Value * q-Value *
Clostridiales Ruminococcaceae 1257 −0.00031 0.00043 0.0064
Clostridiales Ruminococcaceae Faecalibacterium 1220 −0.00022 0.00097 0.0016
CE, coefficient. * Adjusted for age, sex, body mass index, smoking status, total white blood cell count, and hematocrit.
The regression CE represents the rate of change in abundance of taxa per 109/L platelets.
3.6. Comparison of the Functional Microbial Composition between the Upper Quartile and Lower Three
Quartiles Groups
We compared functional profiles generated by PICRUSt between the upper Q and the lower 3Q
groups. The predicted functions of the gut microbiota in the upper Q and lower 3Q groups were
similar based on KEGG ortholog composition, with only subtle statistical differences observed based
on unadjusted p-values. Based on level two profile analysis, PICRUSt predicted a higher abundance of
genes in the ‘Infectious diseases’ KEGG pathway in the upper Q group compared to the lower 3Q group.
Based on level three profile analysis, genes related to the ‘Nitrogen metabolism’ pathway were highly
enriched in the upper Q group, while the pathway related to “Glycosphingolipid biosynthesis-lacto
and neolacto series” was enriched in the lower 3Q group.
Subgroup analysis of men only indicated that in the lower 3Q group, there were very subtle
increases in the genes involved in the ‘Glycosphingolipid biosynthesis–lacto and neolacto series’
pathway that were significant following adjustment compared with the upper group (difference:
4.50 × 10−7, 95% confidential interval: 2.22 × 10−7 to 6.78 × 10−7, adjusted p = 0.038; Supplementary
Figure S6). Among women, we found that several pathways related to the immune system, infectious
diseases, and energy metabolism were higher in the upper Q group than in the lower 3Q groups;
however, these differences were only supported by unadjusted p-values.
4. Discussion
This large cohort study demonstrated that increased platelet count was associated with decreased
diversity of the gut microbiota in a Korean population. The gut microbiota composition also changed
according to platelet level. In particular, there was a negative correlation between platelet count and
genus Faecalibacterium. In subgroup analyses according to sex, diversity was significantly different
between the upper Q and lower 3Q groups in men, whereas only differences in composition were
observed between the two groups in women. Comparative analysis of functional composition revealed
some differences between the two groups, but these differences were not statistically significant.
In this study, platelet count was inversely correlated with the relative abundance of
Faecalibacterium prausnitzii; the sole known species of Faecalibacterium is one of the major butyrate
producers of gut microbiota [45]. Among short-chain fatty acids (SCFAs), microbiota-induced
fermentation products such as butyrate are a main energy source for colonocytes and can promote
a healthy gut through anti-inflammatory action [46]. F. prausnitzii plays a beneficial role in the
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intestine by secreting butyrate with unidentified metabolites [47]. Furthermore, because its abundance
is reduced in several intestinal diseases, including IBD and colon cancer [47,48], F. prausnitzii has
potential as a biomarker for gut health. It is possible that the association between F. prausnitzii and
platelets may be the reason that platelet count is associated with IBD prognosis [49]. Interestingly,
elevated platelet counts are related to prognosis in diabetic patients [50,51], in whom the abundance of
F. prausnitzii is lower compared with non-diabetic patients and inversely correlated with inflammatory
markers such as interleukin-6 (IL-6) and hs-CRP [52]. Given the association between platelet count and
several diseases in which the abundance of F. prausnitzii correlates with prognosis or disease severity,
platelet count might be suppressed by the anti-inflammatory activity of F. prausnitzii [46]. Consistent
with this, a decrease in IL-6, which promotes platelet production [53], was observed after treatment
with F. prausnitzii in a mouse model [54].
Our study demonstrated that the alpha diversity in the upper Q group was reduced compared
with the lower 3Q group. This finding suggests that the composition of the gut microbiota might
be affected by platelet count and/or could contribute to thrombocytosis. Reduced diversity of
the gut microbiota often leads to outgrowth of a few species and decreased resilience, which
can be unhealthy [55,56]. Several chronic diseases including obesity, IBD, diabetes, and atopic
eczema, with increased prevalence in recent decades have been linked to low diversity of the
gut microbiota [1,57–59]. In addition, low gut microbiome diversity is associated with increased
mortality in some clinical conditions such as allogenic hematopoietic stem cell transplantation and
graft-versus-host disease [60,61]. Taken together, increased platelet count could represent a reduction
in gut diversity.
According to our results, expression of genes related to the ‘Glycospingolipid biosynidesis–lacto
and neolacto series’ pathway was increased in the male lower 3Q group compared with the male
upper Q group. Glycospingolipids (GSLs) are a subtype of glycolipids found in the cell membrane
of human and bacterial cells that comprise a ceramide backbone covalently bonded to a glycan
moiety. GSL biosynthesis is a stepwise process, characterized by first adding sugars to ceramides
followed by glycan growth [62]. Among GSLs during this synthesis process, GM1 [63], GD1a, GD1b,
and GT1b [64] suppress platelet-derived growth factor (PDGF)-dependent cell growth and receptor
tyrosine phosphorylation. PDGF, which is released from platelets, stimulates the proliferation of
megakaryocytes in vitro [65], while PDGF knockout leads to thrombocytopenia in mouse embryos [66].
Furthermore, there are several clinical conditions related to thrombocytosis as well as essential
thrombocythemia that lead to increased PDGF levels [67–70]. Overall, gut microbiota might induce
thrombocytosis by generating GSLs that inhibit PDGF activity.
Although a normal platelet count generally ranges from 150 to 450 × 109/L [71], there are
sex-specific differences in normal platelet count. Specifically, women have a slightly higher platelet
count than men [23]. In our study, the greater number of women in the upper Q group was attributed
to the higher third quartile value in women than in men (294 [women] vs. 268 × 109/L [men]). This
imbalanced gender distribution also resulted in differences in hematocrit, iron, and ferritin between
the upper Q and lower Q groups because the women in our study were mostly young, healthy,
premenopausal women with potential iron deficiency anemia (IDA). In IDA women, platelet counts
are inversely correlated with hematocrit and iron [72,73], which supports our findings. However,
these factors are unlikely to have significantly impacted our results because the microbial diversity
differences between the upper and lower groups were only found in men and all subjects and not in
women. The lack of statistical differences in women could be attributed to the relatively small number
of subjects. Compositional differences between the two groups were noticeable in women, possibly
due to the wider distribution of platelets (mean ± SD: 261.2 ± 56.2 (women) vs. 238.8 ± 47.6 × 109/L
(men), p < 0.001). Therefore, in women, the extreme distributional differences in platelet counts may
have contributed to the significant differences observed in the composition of the microbiota.
Our study had several limitations. First, this was a single center, cross-sectional retrospective
study without longitudinal follow-up data. Therefore, we could not determine whether platelet
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changes or gut microbiome changes occurred first. However, we assumed that gut microbiome affects
platelet count through microbial functional pathway analysis. Second, our study was conducted on
a relatively healthy population and therefore did not include patients with thrombocytosis meeting
the common definition (>500 × 109/L). We only demonstrated that a relative elevation of platelets
within normal range was linked to a potentially characteristic gut environment. To investigate the
association between the gut microbiome and thrombocytosis, further studies are required. Third,
we identified the quantitative association between platelet count and the gut microbiome but did not
confirm any qualitative association. Since platelets are functionally independent from their count [74],
subjects with platelet function defects might have influenced the results of our study. To reduce this
possibility, subjects receiving medications that would affect platelet function were excluded from our
study. Lastly, the baseline characteristics between the upper Q and lower 3Q groups were not identical;
in particular, gender distribution was varied. Those differences might have affected gut microbiome
analyses. Therefore, we analyzed the diversity and composition of the gut microbiome separately in
men and women. Linear correlation was also adjusted by sex, age, BMI, smoking status, WBC count,
and hematocrit to control for any additional confounders.
5. Conclusions
In summary, the diversity and composition of the gut microbiome in patients with increased
platelet counts were distinct from those with lower platelet counts. The genus Faecalibacterium,
which contains the species F. prausnitzii with beneficial effects on gut, was negatively correlated
with platelet count, potentially due to its anti-inflammatory function. Overall, we firstly report an
association between gut microbiota and platelet count, which suggests that gut microbiota might
influence platelet count systemically. Thus, platelet count could be a biomarker for detecting changes
in gut microbiota, even in populations with platelet counts within relatively normal range. Additional
studies are needed to confirm the antecedent association and mechanism between platelets and
gut microbiota
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